| Description | MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury. |
| In vitro | MK-0159 (0-50 μM，24 小时)能增加 A549 细胞和 HMVEC 细胞内外的 NAD+[1]。 |
| In vivo | 在心肌缺血/再灌注损伤小鼠中，MK-0159（30 mg/kg；口服）能够减小梗死面积[1]。 |
| Target activity | CD38 (mouse):3 nM, CD38 (human):22±5 nM, CD38 (rat):70 nM |
| molecular weight | 400.495 |
| Molecular formula | C20H24N4O3S |
| CAS | 2641484-61-7 |
| Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 80 mg/mL (199.75 mM), Sonification is recommended. |
| References | 1. Lagu B, et al. Orally Bioavailable Enzymatic Inhibitor of CD38, MK-0159, Protects against Ischemia/Reperfusion Injury in the Murine Heart. J Med Chem. 2022 Jun 28. 2. Chen PM, et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci Adv. 2022 Jun 17;8(24):eabo4271. |